表紙
市場調査レポート

薬剤溶出ステント (DES):パイプライン分析

Drug Eluting Stents (DES) - Pipeline Review, 2015

発行 GlobalData 商品コード 328676
出版日 ページ情報 英文 210 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
薬剤溶出ステント (DES):パイプライン分析 Drug Eluting Stents (DES) - Pipeline Review, 2015
出版日: 2015年03月20日 ページ情報: 英文 210 Pages
概要

当レポートでは、世界各国の企業・医療機関などで開発中の薬剤溶出ステント (DES) のパイプライン製品情報について分析し、治験/製品開発の全体的な進行状況や、段階別・地域別・分野別の詳細動向、企業別・製品別の詳細情報 (治験の進行段階、開始/終了時期、認証見通しなど)、昨今の開発・資本取引の動きなどを盛り込んでお届けいたします。

目次

  • イントロダクション
    • 薬剤溶出ステント (DES) の概要
  • 開発中の製品
    • パイプライン製品:開発段階別
    • パイプライン製品:セグメント別
    • パイプライン製品:地域別
    • パイプライン製品:規制経路別
    • パイプライン製品:認証時期 (推定) 別
    • パイプライン製品:進行中の治験
  • 薬剤溶出ステント:開発中のパイプライン製品 (企業別)
    • 薬剤溶出ステントの開発企業:パイプライン製品 (開発段階別)
    • 薬剤溶出ステント:開発段階別のパイプライン製品
  • 薬剤溶出ステントの開発企業・製品の概要
  • Abbott Vascular Inc.
    • パイプライン製品/進行中の治験の概要
  • AlviMedica Medical Technologies Inc.
  • Amaranth Medical, Inc.
  • Arterius Ltd
  • Biosensors International Group, Ltd.
  • BioSurfaces, Inc.
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • CARDIONOVUM GmbH
  • CID S.r.l.
  • Contego Medical, LLC
  • DISA Vascular (Pty) Ltd.
  • Elixir Medical Corporation
  • Envision Scientific Pvt. Ltd
  • Eurocor GmbH
  • HangZhou HuaAn Biotechnology Co.,Ltd
  • Icon Interventional Systems, Inc.
  • ICON Medical Corp.
  • InspireMD, Inc.
  • IRAMED GmbH
  • Lepu Medical Technology (Beijing) Co., Ltd.
  • Medinol Ltd.
  • Medtronic plc
  • Meril Life Sciences Pvt. Ltd.
  • Micell Technologies, Inc.
  • Minvasys
  • NanoCoeur, Inc.
  • Northwestern University
  • OrbusNeich
  • REVA Medical, Inc.
  • Sino Medical-Device Technology Co., Ltd.
  • Stentys, SA
  • Svelte Medical Systems, Inc.
  • Tepha, Inc.
  • テルモ
  • Tryton Medical, Inc.
  • University of Strathclyde
  • VasoTech Inc.
  • Xenogenics Corporation
  • Zorion Medical
  • 昨今の動向 (計71件)
  • 付録

図表一覧

目次
Product Code: GDME0002EPD

GlobalData's Medical Devices sector report, "Drug Eluting Stents (DES) - Pipeline Review, 2015" provides an overview of Drug Eluting Stents currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key drug eluting stents pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Drug Eluting Stents products under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Drug Eluting Stents and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Drug Eluting Stents under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Drug Eluting Stents (DES) Overview
  • Products under Development
    • Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
    • Drug Eluting Stents (DES) - Pipeline Products by Segment
    • Drug Eluting Stents (DES) - Pipeline Products by Territory
    • Drug Eluting Stents (DES) - Pipeline Products by Regulatory Path
    • Drug Eluting Stents (DES) - Pipeline Products by Estimated Approval Date
    • Drug Eluting Stents (DES) - Ongoing Clinical Trials
  • Drug Eluting Stents (DES) - Pipeline Products under Development by Companies
    • Drug Eluting Stents (DES) Companies - Pipeline Products by Stage of Development
    • Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
  • Drug Eluting Stents (DES) Companies and Product Overview
  • Abbott Vascular Inc. Company Overview
    • Abbott Vascular Inc. Pipeline Products & Ongoing Clinical Trials Overview
    • Abbott Vascular Inc. - Ongoing Clinical Trials Overview
      • Absorb Bioresorbable Vascular Scaffold Clinical Trial Details
  • AlviMedica Medical Technologies Inc. Company Overview
    • AlviMedica Medical Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
    • AlviMedica Medical Technologies Inc. - Ongoing Clinical Trials Overview
      • Cre8 DES Clinical Trial Details
  • Amaranth Medical, Inc. Company Overview
    • Amaranth Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
      • Amaranth Medical, Inc. - Ongoing Clinical Trials Overview
      • FORTITUDE Scaffold Ongoing Clinical Trial Details
      • Next Generation FORTITUDE Scaffold Ongoing Clinical Trial Details
  • Arterius Ltd Company Overview
    • Arterius Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Biosensors International Group, Ltd. Company Overview
    • Biosensors International Group, Ltd. Pipeline Products & Ongoing Clinical Trials Overview
    • Biosensors International Group, Ltd. - Ongoing Clinical Trials Overview
      • BioFreedom Drug Coated Stent Clinical Trial Details
      • Excel II DES Ongoing Clinical Trial Details
  • BioSurfaces, Inc. Company Overview
    • BioSurfaces, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Biotronik SE & Co. KG Company Overview
    • Biotronik SE & Co. KG Pipeline Products & Ongoing Clinical Trials Overview
    • Biotronik SE & Co. KG - Ongoing Clinical Trials Overview
      • Orsiro Hybrid Drug Eluting Stent Clinical Trial Details
  • Boston Scientific Corporation Company Overview
    • Boston Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview
    • Boston Scientific Corporation - Ongoing Clinical Trials Overview
      • SYNERGY Everolimus-Eluting Stent System Clinical Trial Details
  • CARDIONOVUM GmbH Company Overview
    • CARDIONOVUM GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • CID S.r.l. Company Overview
    • CID S.r.l. Pipeline Products & Ongoing Clinical Trials Overview
  • Contego Medical, LLC Company Overview
    • Contego Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview
  • DISA Vascular (Pty) Ltd. Company Overview
    • DISA Vascular (Pty) Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Elixir Medical Corporation Company Overview
    • Elixir Medical Corporation Pipeline Products & Ongoing Clinical Trials Overview
    • Elixir Medical Corporation - Ongoing Clinical Trials Overview
      • DESyne BD Novolimus Eluting Coronary Stent System Ongoing Clinical Trial Details
      • DESyne Nx Novolimus Eluting Coronary Stent System Ongoing Clinical Trial Details
      • DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System Ongoing Clinical Trial Details
  • Envision Scientific Pvt. Ltd Company Overview
    • Envision Scientific Pvt. Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Eurocor GmbH Company Overview
    • Eurocor GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • HangZhou HuaAn Biotechnology Co.,Ltd Company Overview
    • HangZhou HuaAn Biotechnology Co.,Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Icon Interventional Systems, Inc. Company Overview
    • Icon Interventional Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • ICON Medical Corp. Company Overview
    • ICON Medical Corp. Pipeline Products & Ongoing Clinical Trials Overview
  • InspireMD, Inc. Company Overview
    • InspireMD, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • IRAMED GmbH Company Overview
    • IRAMED GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • Lepu Medical Technology (Beijing) Co., Ltd. Company Overview
    • Lepu Medical Technology (Beijing) Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
    • Lepu Medical Technology (Beijing) Co., Ltd. - Ongoing Clinical Trials Overview
      • Nano+ Stent Ongoing Clinical Trial Details
  • Medinol Ltd. Company Overview
    • Medinol Ltd. Pipeline Products & Ongoing Clinical Trials Overview
    • Medinol Ltd. - Ongoing Clinical Trials Overview
      • NIRsupreme Ridaforolimus-Eluting Coronary Stent System Clinical Trial Details
  • Medtronic plc Company Overview
    • Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview
  • Meril Life Sciences Pvt. Ltd. Company Overview
    • Meril Life Sciences Pvt. Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Meril Life Sciences Pvt. Ltd. - Ongoing Clinical Trials Overview
    • BioMime Ongoing Clinical Trial Details
  • Micell Technologies, Inc. Company Overview
    • Micell Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Minvasys Company Overview
    • Minvasys Pipeline Products & Ongoing Clinical Trials Overview
  • NanoCoeur, Inc. Company Overview
    • NanoCoeur, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Northwestern University Company Overview
    • Northwestern University Pipeline Products & Ongoing Clinical Trials Overview
  • OrbusNeich Company Overview
    • OrbusNeich Pipeline Products & Ongoing Clinical Trials Overview
    • OrbusNeich - Ongoing Clinical Trials Overview
      • COMBO Dual Therapy Stent Clinical Trial Details
  • REVA Medical, Inc. Company Overview
    • REVA Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Sino Medical-Device Technology Co., Ltd. Company Overview
    • Sino Medical-Device Technology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Stentys, SA Company Overview
    • Stentys, SA Pipeline Products & Ongoing Clinical Trials Overview
  • Svelte Medical Systems, Inc. Company Overview
    • Svelte Medical Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Tepha, Inc. Company Overview
    • Tepha, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Terumo Corporation Company Overview
    • Terumo Corporation Pipeline Products & Ongoing Clinical Trials Overview
    • Terumo Corporation - Ongoing Clinical Trials Overview
      • Ultimaster Ongoing Clinical Trial Details
  • Tryton Medical, Inc. Company Overview
    • Tryton Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • University of Strathclyde Company Overview
    • University of Strathclyde Pipeline Products & Ongoing Clinical Trials Overview
  • VasoTech Inc. Company Overview
    • VasoTech Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Xenogenics Corporation Company Overview
    • Xenogenics Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Zorion Medical Company Overview
    • Zorion Medical Pipeline Products & Ongoing Clinical Trials Overview
  • Drug Eluting Stents (DES)- Recent Developments
    • Mar 02, 2015: Tryton Medical Announces Publication of Data from Pivotal Trial for Tryton Side Branch Stent in Journal of American College of Cardiology
    • Feb 23, 2015: REVA Bioresorbable Program Update at CRT Conference
    • Feb 19, 2015: BIOTRONIK Advances Clinical Evaluation of Latest Generation DREAMS, World's First Bioabsorbable Magnesium Scaffold
    • Feb 13, 2015: COMBO Dual Therapy Stent - Three-year Data featured at JIM 2015
    • Feb 12, 2015: Svelte Medical Systems and ASAHI INTECC Announce Manufacturing and Co-Branding Agreements
    • Feb 12, 2015: Biosensors Reports Financial Results for the Third Quarter of Fiscal Year 2015
    • Feb 09, 2015: LEADERS Free Japan Trial Completes Enrollment
    • Feb 04, 2015: Micell Technologies MiStent SES Now Commercially Available in Europe
    • Feb 04, 2015: BIOTRONIK Announces Completion of Patient Enrollment in BIOFLOW-IV Study Evaluating Safety and Efficacy of Orsiro
    • Jan 29, 2015: Abbott Reports Fourth-Quarter 2014 Results
    • Jan 23, 2015: MicroPort Receives CE Mark Approval for Firehawk
    • Jan 20, 2015: Mr. Aurelio Sahagun Promoted to COO of MicroPort Orthopedics
    • Jan 16, 2015: Eurocor Receives CE Mark Approval for E-Magic Plus SES
    • Jan 06, 2015: Biosensors Announces CTO'S Retirement
    • Jan 05, 2015: Acacia Subsidiary Enters into Settlement and Patent License Agreement with Cordis
    • Jan 04, 2015: Firehawk Gains CFDA Approval to Offer More Specifications
    • Dec 11, 2014: COMBO Dual Therapy Stent Healing Benefits Highlighted at GulfPCR-GIM 2014
    • Dec 03, 2014: REVA Implants First Patients With Fantom Scaffold
    • Dec 02, 2014: Terumo receives CE Mark approval for the line extension on Drug-eluting Stent, Ultimaster to advance the treatment of coronary artery disease
    • Nov 19, 2014: New Data From EVOLVE Clinical Program Demonstrate SYNERGY Bioabsorbable Polymer Stent Meets Key Performance Endpoints
    • Nov 12, 2014: Biosensors Reports Financial Results for the Second Quarter and First Half of Fiscal Year 2015
    • Nov 05, 2014: ClearStream Technologies Expands Enniscorthy Facility
    • Nov 04, 2014: Boston Scientific To Host And Webcast Investor Event
    • Nov 03, 2014: Micell Technologies Announces Plans for MiStent SES Commercial Launch
    • Nov 03, 2014: Medtronic Secures CE Mark For Resolute Onyx Drug-eluting Stent
    • Nov 03, 2014: STENTYS Expands Product Offering To All Coronary Stent Indications Through Exclusive Agreement With Micell To Distribute Its Novel Drug-Eluting Stent
    • Oct 27, 2014: STENTYS' Sirolimus-Eluting Stent Receives CE Marking
    • Oct 20, 2014: Boston Scientific Initiates Study Of Promus PREMIER Coronary Stent System In Underserved Patient Populations
    • Oct 17, 2014: COMBO Dual Therapy Stent - A Long-term Solution to Vessel Restoration
    • Oct 10, 2014: BIOTRONIK to Offer New Treatment Options in France with Release of Orsiro Drug-Eluting Stent
    • Sep 18, 2014: Latest Data Shows OrbusNeich's COMBO Dual Therapy Stent has Excellent Healing Benefits
    • Sep 18, 2014: World's First Integrated Delivery System Meets All Endpoints in the Direct II Randomized, Controlled Drug-Eluting Coronary Stent Study
    • Sep 16, 2014: REVA Presents Fantom Scaffold Program at TCT 2014 Conference
    • Sep 16, 2014: Micell Technologies Highlights Positive Three-Year Data from MiStent SES DESSOLVE Clinical Studies at TCT 2014
    • Sep 16, 2014: Amaranth Medical Initiates Clinical Trial of the Second-Generation FORTITUDE Bioresorbable Drug-Eluting Scaffold
    • Sep 15, 2014: Abbott Initiates ABSORB IV Trial to Evaluate Quality of Life and Cost Savings of Dissolving Heart Device
    • Sep 14, 2014: ABSORB II Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent
    • Sep 10, 2014: Tryton Medical Enrolls First U.S. Patient in the EXTENDED ACCESS Registry
    • Sep 10, 2014: Global Bifurcation Leader Tryton Medical Announces Events at TCT 2014
    • Sep 08, 2014: Elixir Medical Announces Schedule of Programs for TCT 2014
    • Sep 04, 2014: Initial Patient Enrolled in BioFreedom USA: First Major American Trial for Biosensors
    • Sep 03, 2014: STENTYS Reaches 10,000 Self-Apposing Stent implantations
    • Sep 01, 2014: BIOSCIENCE Trial Further Confirms Orsiro as Best in Class
    • Sep 01, 2014: Biosensors Welcomes New CEO
    • Aug 06, 2014: Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2015
    • Jul 28, 2014: Tryton Medical Enrolls First Patient in the EXTENDED Access Registry
    • Jul 16, 2014: First patient enrollment in MASCOT registry represents major milestone for COMBO Dual Therapy Stent and OrbusNeich's clinical program
    • Jul 10, 2014: Abbott Builds Long Term Commitment In China
    • Jul 09, 2014: Micell Technologies Adds to Portfolio of Intellectual Property Protection
    • Jul 09, 2014: STENTYS Expands Marketing of the Self-Apposing Stent in South America
    • Jun 24, 2014: Abbott Announces Job Reductions At Lake County Headquarters In US
    • Jun 17, 2014: Biosensors Leaders Free Japan Trial Enrolls First Patient
    • Jun 12, 2014: First Patient Enrolled in Investigator Initiated REDUCE Study
    • Jun 02, 2014: Stentys Completes Acquisition of Cappella Peel Away from Cappella for USD1.4 Million
    • May 29, 2014: Svelte Medical Systems Announces Completion of 6-Month Follow-up in the DIRECT II Drug-Eluting Stent Study
    • May 28, 2014: Biosensors Reports Financial Results for Fiscal Year 2014
    • May 28, 2014: Biosensors Announces Appointment of New CEO
    • May 27, 2014: STENTYS Self-Apposing Stent Featured Prominently at 2014 EuroPCR Conference
    • May 23, 2014: OrbusNeich Releases Long-term Data for World's First and Only Dual Therapy Stent
    • May 23, 2014: Micell Technologies Announces Positive Long-Term Data from MiStent SES Clinical Studies Presented at EuroPCR 2014
    • May 23, 2014: Elixir Medical Announces Clinical Trial Results of DESyne BD Novolimus Eluting Coronary Stent System at EuroPCR
    • May 23, 2014: Elixir Medical Announces Results for CE mark-approved DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System at EuroPCR
    • May 23, 2014: Elixir Medical Announces Outstanding Long-Term Clinical Results at EuroPCR for World's Broadest Portfolio of Three CE Mark-Approved Novolimus Eluting Coronary Intervention Systems
    • May 22, 2014: REVA Holds Sponsored Symposium at EuroPCR
    • May 22, 2014: Complex Lesion BIOFLOW-III Subgroup Analyses Further Support Top Performance of BIOTRONIK Orsiro
    • May 21, 2014: Successful Live Case Demonstration of Elixir Medical's CE Mark-Approved Fully Bioresorbable DESolve 100 Novolimus Eluting Coronary Scaffold System at EuroPCR
    • May 21, 2014: Boston Scientific Reports Strong Performance Data For SYNERGY Stent System
    • May 21, 2014: Biosensors Leaders Free Patient Population Data Presented at EuroPCR Enrollment Now Complete
    • May 21, 2014: Small Vessel BIOFLOW-II Subgroup Analyses Demonstrate Top Performance of BIOTRONIK Orsiro
    • May 20, 2014: STENTYS Sirolimus-Eluting Stent Demonstrates Best in Class Efficacy for Heart Attack Patients
    • May 15, 2014: Micell Technologies Announces Clinical Data from MiStent SES Studies Will Be Presented at EuroPCR 2014
    • May 14, 2014: Elixir Medical to Showcase a Live Case Demonstration of the Breakthrough Fully Bioresorbable DESolve 100 Novolimus Eluting Coronary Scaffold System at EuroPCR
    • May 13, 2014: Elixir Medical's DESolve 100 Novolimus Eluting Coronary Scaffold System Gets CE Mark
    • May 06, 2014: STENTYS: Journal of the American College of Cardiology Publication Shows Malapposition Influences Death from Early Stent Thrombosis
    • May 05, 2014: USFDA Grants IDE Approval For Biosensors' BioFreedom US Feasibility Trial
    • May 01, 2014: Boston Scientific Launches Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System In Japan
    • Apr 29, 2014: STENTYS' Self-Apposing Stent Featured in New Article Published by the Journal of the American College of Cardiology
    • Apr 28, 2014: MicroPort Released New Products to its Nationwide Distributors
    • Apr 10, 2014: Abbott Completes Enrollment of Absorb Randomized Clinical Trials in the United States, Japan and China
    • Mar 28, 2014: Patient Enrollment Completed in Multicenter European REMEDEE Registry of OrbusNeich's COMBO Dual Therapy Stent
    • Mar 27, 2014: Arterial Remodeling Technologies Enters Into Co-Development Agreement With Terumo For Bioresorbable Scaffold
  • Appendix
  • Methodology
  • Keywords:
  • About GlobalData
  • Contact Us
  • Disclaimer

List of Tables

  • Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
  • Drug Eluting Stents (DES) - Pipeline Products by Segment
  • Drug Eluting Stents (DES) - Pipeline Products by Territory
  • Drug Eluting Stents (DES) - Pipeline Products by Regulatory Path
  • Drug Eluting Stents (DES) - Pipeline Products by Estimated Approval Date
  • Drug Eluting Stents (DES) - Ongoing Clinical Trials
  • Drug Eluting Stents (DES) Companies - Pipeline Products by Stage of Development
  • Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
  • Abbott Vascular Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Absorb Bioresorbable Vascular Scaffold - Product Status
  • Absorb Bioresorbable Vascular Scaffold - Product Description
  • XIENCE Thinman DES - Product Status
  • XIENCE Thinman DES - Product Description
  • Abbott Vascular Inc. - Ongoing Clinical Trials Overview
  • Absorb Bioresorbable Vascular Scaffold - A Clinical Evaluation of Absorb BVS, the Bioresorbable Vascular Scaffold, in the Treatment of Subjects With de Novo Native Coronary Artery Lesions in Chinese Population
  • Absorb Bioresorbable Vascular Scaffold - A Clinical Evaluation of Absorb BVS, The Everolimus Eluting Bioresorbable Vascular Scaffold In The Treatment Of Subjects With De Novo Native Coronary Artery Lesions
  • Absorb Bioresorbable Vascular Scaffold - A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de Novo Native Coronary Artery Lesions
  • Absorb Bioresorbable Vascular Scaffold - A Clinical Evaluation of AVJ-301 (Absorb BVS), The Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions in Japanese Population
  • Absorb Bioresorbable Vascular Scaffold - A Clinical Evaluation to Compare the Safety, Efficacy and Performance of ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System Against XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Subjects with Ischemic Heart Disease Caused by de Novo Native Coronary Artery Lesions: ABSORB II Randomized Controlled Trial
  • Absorb Bioresorbable Vascular Scaffold - A Continuation in the Clinical Evaluation of the Abbott Vascular Everolimus-Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions: ABSORB EXTEND Clinical Investigation
  • Absorb Bioresorbable Vascular Scaffold - A Multicentre Prospective Natural History Study Using Multimodality Imaging in Patients with Acute Coronary Syndromes - PROSPECT II (Natural History Study) Combined with a Randomized, Controlled, Intervention Study - PROSPECT ABSORB (Randomized Trial)
  • Absorb Bioresorbable Vascular Scaffold - A Post-market Registry of Patients with de Novo Lesions in Previously Untreated Vessels Treated with Absorb BVS
  • Absorb Bioresorbable Vascular Scaffold - Amsterdam Investigator-initiated Absorb Strategy All-comers Trial (AIDA Trial): A Clinical Evaluation Comparing the Efficacy and Performance of ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold Strategy Versus the XIENCE Family (XIENCE PRIME or XIENCE Xpedition) Everolimus Eluting Coronary Stent Strategy in the Treatment of Coronary Lesions in Consecutive All-comers
  • Absorb Bioresorbable Vascular Scaffold - An International Post-market Registry of Patients With de Novo Lesions in Previously Untreated Vessels Treated With Absorb Bioresorbable Vascular Scaffold (Absorb BVS): ABSORB FIRST Registry
  • Absorb Bioresorbable Vascular Scaffold - Comparison of the ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System With a Drug- Eluting Metal Stent (Xience) in Acute ST-Elevation Myocardial Infarction
  • Absorb Bioresorbable Vascular Scaffold - Comprehensive Imaging and Interventional Therapy Studies for Arteriogenic Erectile Dysfunction and Lower Urinary Tract Symptoms: a Multi-modality, Multi-specialty Collaborative Study (PERFECT Program)
  • Absorb Bioresorbable Vascular Scaffold - Everolimus-eluting Bioresorbable Vascular Scaffold System in the Treatment of Cardiac Allograft Vasculopathy in Heart Transplant Recipients: A Prospective Multicenter Pilot Study
  • Absorb Bioresorbable Vascular Scaffold - German-Austrian Register to Evaluate the Short and Long-term Safety and Therapy Outcomes of the ABSORB Everolimus-Eluting Bioresorbable Vascular Scaffold System in Patients With Coronary Artery Stenosis
  • Absorb Bioresorbable Vascular Scaffold - Impact of Vascular Reparative Therapy on Vasomotor Function and Myocardial Perfusion: A Randomized H215O PET/CT Study
  • Absorb Bioresorbable Vascular Scaffold - Intracoronary Scaffold Assessment a Randomised Evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI): A Prospective, Randomized Trial of BVS Veruss EES in Patients Undergoing Coronary Stenting for Myocardial Infarction
  • Absorb Bioresorbable Vascular Scaffold - Performance of Bioresorbable Scaffold in Primary Percutaneous Intervention of ST Elevation Myocardial Infarct (BVS in STEMI)
  • AlviMedica Medical Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Coracto Rapamycin-Eluting Coronary Stent - Product Status
  • Coracto Rapamycin-Eluting Coronary Stent - Product Description
  • Cre8 DES - Product Status
  • Cre8 DES - Product Description
  • AlviMedica Medical Technologies Inc. - Ongoing Clinical Trials Overview
  • Cre8 DES - A Prospective, Multi-center, Randomized Controlled Trial Evaluating the Safety and Efficacy of the CRE8 Sirolimus-Eluting Stent Versus the RESOLUTE Zotarolimus-eluting Stent in the Treatment of Patients with De Novo Coronary Artery Lesions
  • Cre8 DES - A Prospective, Multi-center, Single-arm Observational Registry Trial Evaluating the Safety and Efficacy of CRE8 Sirolimus-Eluting Stent in the Treatment of Patients With De Novo Coronary Artery Lesions
  • Cre8 DES - A Prospective, Single Center, Open Label, Randomized Controlled, Two Arm Study Evaluating Safety and Efficacy of the Permanent Polymer Zotarolimus Eluting Stent Resolute Integrity Compared to the Polymer Free Amphilimus Eluting Stent Cre8
  • Amaranth Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • FORTITUDE Scaffold - Product Status
  • FORTITUDE Scaffold - Product Description
  • Next Generation FORTITUDE Scaffold - Product Status
  • Next Generation FORTITUDE Scaffold - Product Description
  • Amaranth Medical, Inc. - Ongoing Clinical Trials Overview
  • FORTITUDE Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - European Trial
  • Next Generation FORTITUDE Scaffold - Amaranth Endovascular Study of a Drug-eluting Bioresorbable Coronary Scaffold
  • Arterius Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Arteriosorb Absorbable Drug-Eluting Scaffold - Product Status
  • Arteriosorb Absorbable Drug-Eluting Scaffold - Product Description
  • Biosensors International Group, Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • BioFreedom Drug Coated Stent - Product Status
  • BioFreedom Drug Coated Stent - Product Description
  • Excel II DES - Product Status
  • Excel II DES - Product Description
  • Biosensors International Group, Ltd. - Ongoing Clinical Trials Overview
  • BioFreedom Drug Coated Stent - A Prospective Randomized Comparison of the BioFreedom Biolimus A9 Drug Coated Stent versus the Gazelle Bare Metal Stent in Patients with High Risk of Bleeding
  • BioFreedom Drug Coated Stent - To Collect Additional Safety and Effectiveness Data for the Biosensors BioFreedom BA9 Drug Coated Coronary Stent in Patients with Native, de Novo Coronary Artery Disease
  • Excel II DES - A Prospective Multicenter Randomized Trial to Assess the Safety and Effectiveness of EXCEL-II Sirolimus Eluting Stent vs. EXCEL Sirolimus Eluting Stent for the Treatment of Patients with de Novo Coronary Artery Lesions (CREDIT II Trial)
  • BioSurfaces, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Drug-Eluting Stent Jacket - Product Status
  • Drug-Eluting Stent Jacket - Product Description
  • Biotronik SE & Co. KG Pipeline Products & Ongoing Clinical Trials Overview
  • DREAMS - Product Status
  • DREAMS - Product Description
  • DREAMS 2 - Product Status
  • DREAMS 2 - Product Description
  • Orsiro Hybrid Drug Eluting Stent - Product Status
  • Orsiro Hybrid Drug Eluting Stent - Product Description
  • Biotronik SE & Co. KG - Ongoing Clinical Trials Overview
  • Orsiro Hybrid Drug Eluting Stent - BIOTRONIK - Safety and Performance Registry for an All-comers Patient Population with the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III French Satellite
  • Orsiro Hybrid Drug Eluting Stent - BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III United Kingdom Satellite
  • Boston Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Next Generation SYNERGY - Product Status
  • Next Generation SYNERGY - Product Description
  • SYNERGY Everolimus-Eluting Stent System - Product Status
  • SYNERGY Everolimus-Eluting Stent System - Product Description
  • Boston Scientific Corporation - Ongoing Clinical Trials Overview
  • SYNERGY Everolimus-Eluting Stent System - A Prospective Optical Coherence Tomography (OCT) Study on Coronary Vessel Wall Response to Stent Eluting Everolimus from a Biodegradable Polymer (EES SYNERGY) Compared with Stent Eluting Zotarolimus from a Durable Polymer (ZES, RESOLUTE Integrity)
  • SYNERGY Everolimus-Eluting Stent System - A Single-Arm Trial to Evaluate the Effectiveness of PCI of de Novo 3-vessel Disease Applying the SYNTAX Score II With Pressure Wire Functional Assessment and IVUS Guidance, Using an Everolimus-eluting Stent With Biodegradable Abluminal Coating
  • SYNERGY Everolimus-Eluting Stent System - Comparison of Titanium-Nitride-Oxide Coated Bio-Active-Stent (Optimax) to the Drug (Everolimus) -Eluting Stent (Synergy) in Acute Coronary Syndrome
  • SYNERGY Everolimus-Eluting Stent System - Conventional Antegrade Vs Sub-intimal Synergy Stenting in Chronic Total Occlusions
  • SYNERGY Everolimus-Eluting Stent System - Improved Drug Eluting Stent for Percutaneous Coronary Intervention of the Left Main Artery in a Real World All-comers Population
  • SYNERGY Everolimus-Eluting Stent System - Randomized Clinical Comparison of Everolimus-eluting SYNERGY and Biolimus-eluting BioMatrix NeoFlex Coronary Stents in Non-selected Patients with Ischemic Heart Disease
  • SYNERGY Everolimus-Eluting Stent System - Randomized Comparison of the Biolimus-eluting Biomatrix Neoflex og Everolimus-eluting SYNERGY Stents in All-comer Patients with Ischemic Heart Disease: The OCT SORT-OUT VIII
  • CARDIONOVUM GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • ReNATURAL (M) - Product Status
  • ReNATURAL (M) - Product Description
  • ReNATURAL (P) - Product Status
  • ReNATURAL (P) - Product Description
  • CID S.r.l. Pipeline Products & Ongoing Clinical Trials Overview
  • Janus Flex - Product Status
  • Janus Flex - Product Description
  • Optima Jet - Product Status
  • Optima Jet - Product Description
  • Contego Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview
  • CORGUARD - Product Status
  • CORGUARD - Product Description
  • DISA Vascular (Pty) Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Stellium Stent - Product Status
  • Stellium Stent - Product Description
  • Elixir Medical Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • DESolve 100 Novolimus Eluting Bioresorbable Coronary Scaffold System - Product Status
  • DESolve 100 Novolimus Eluting Bioresorbable Coronary Scaffold System - Product Description
  • DESolve Myolimus Eluting Bioresorbable Coronary Scaffold System - Product Status
  • DESolve Myolimus Eluting Bioresorbable Coronary Scaffold System - Product Description
  • DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System - Product Status
  • DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System - Product Description
  • DESyne BD Novolimus Eluting Coronary Stent System - Product Status
  • DESyne BD Novolimus Eluting Coronary Stent System - Product Description
  • DESyne Nx Novolimus Eluting Coronary Stent System - Product Status
  • DESyne Nx Novolimus Eluting Coronary Stent System - Product Description
  • Myolimus Eluting Coronary Stent - Durable Polymer - Product Status
  • Myolimus Eluting Coronary Stent - Durable Polymer - Product Description
  • Elixir Medical Corporation - Ongoing Clinical Trials Overview
  • DESyne BD Novolimus Eluting Coronary Stent System - Post Marketing Study of the Elixir Desyne Novolimus Eluting Coronary Stent System and the Desyne BD Novolimus Eluting Coronary Stent System in the Treatment of Patients with De Novo Native Coronary Artery Lesions
  • DESyne Nx Novolimus Eluting Coronary Stent System - Evaluation of the Novolimus-Eluting Coronary Stent System: A Randomized Study
  • DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System - Post-market Evaluation of Desolve Novolimus Eluting Bioresorbable Coronary Scaffold System in the Treatment of Patients with De Novo Native Coronary Artery Lesions
  • Envision Scientific Pvt. Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • FOCUS np - Product Status
  • FOCUS np - Product Description
  • Eurocor GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • Genius TAXCOR - Product Status
  • Genius TAXCOR - Product Description
  • HangZhou HuaAn Biotechnology Co.,Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Xinsorb BRS - Product Status
  • Xinsorb BRS - Product Description
  • Icon Interventional Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Biosorb - Product Status
  • Biosorb - Product Description
  • ICON Medical Corp. Pipeline Products & Ongoing Clinical Trials Overview
  • Nuloy DES - Product Status
  • Nuloy DES - Product Description
  • InspireMD, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Mguard Drug Eluting Stent - Product Status
  • Mguard Drug Eluting Stent - Product Description
  • IRAMED GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • EasyRap - Product Status
  • EasyRap - Product Description
  • FlexyRap - Product Status
  • FlexyRap - Product Description
  • MovyTax - Product Status
  • MovyTax - Product Description
  • Lepu Medical Technology (Beijing) Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Nano+ Stent - Product Status
  • Nano+ Stent - Product Description
  • Lepu Medical Technology (Beijing) Co., Ltd. - Ongoing Clinical Trials Overview
  • Nano+ Stent - Efficacy and Safety of Nano+ Polymer-free Sirolimus-Eluting Stent in the Treatment of Patients With De Novo Lesion: A Optical Coherent Tomography Prospective, Multicenter Study
  • Medinol Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • NIRsupreme Ridaforolimus-Eluting Coronary Stent System - Product Status
  • NIRsupreme Ridaforolimus-Eluting Coronary Stent System - Product Description
  • Medinol Ltd. - Ongoing Clinical Trials Overview
  • NIRsupreme Ridaforolimus-Eluting Coronary Stent System - BioNIR Ridaforolimus Eluting Coronary Stent System (BioNIR) European Angiography Study
  • NIRsupreme Ridaforolimus-Eluting Coronary Stent System - BioNIR Ridaforolimus Eluting Coronary Stent System (BioNIR) in Coronary Stenosis Trial
  • Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview
  • Next Generation Coronary Stent - Product Status
  • Next Generation Coronary Stent - Product Description
  • Resolute Onyx - Product Status
  • Resolute Onyx - Product Description
  • Meril Life Sciences Pvt. Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • BioMime - Product Status
  • BioMime - Product Description
  • BIOMIME AURA - Product Status
  • BIOMIME AURA - Product Description
  • MeRes - Product Status
  • MeRes - Product Description
  • MITSU - Product Status
  • MITSU - Product Description
  • Meril Life Sciences Pvt. Ltd. - Ongoing Clinical Trials Overview
  • BioMime - A Prospective, Active Control Open Label, Multicentre Randomized Clinical Trial for Comparison Between BioMime Sirolimus Eluting Stent of and Xience Everolimus Eluting Stent to Evaluate Efficacy and Safety in Coronary Artery Disease
  • Micell Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • MiStent Sirolimus Eluting Coronary Stent System - Product Status
  • MiStent Sirolimus Eluting Coronary Stent System - Product Description
  • Minvasys Pipeline Products & Ongoing Clinical Trials Overview
  • Nile LM SIR Sirolimus Eluting Intracoronary Stent - Product Status
  • Nile LM SIR Sirolimus Eluting Intracoronary Stent - Product Description
  • Nile SIR Sirolimus Eluting Intracoronary Stent - Product Status
  • Nile SIR Sirolimus Eluting Intracoronary Stent - Product Description
  • NanoCoeur, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Nanocoating Cardiac Stent - Product Status
  • Nanocoating Cardiac Stent - Product Description
  • Northwestern University Pipeline Products & Ongoing Clinical Trials Overview
  • NO - Eluting Biodegradable PDC Stent - Product Status
  • NO - Eluting Biodegradable PDC Stent - Product Description
  • OrbusNeich Pipeline Products & Ongoing Clinical Trials Overview
  • Acute BRS - Product Status
  • Acute BRS - Product Description
  • COMBO Dual Therapy Stent - Product Status
  • COMBO Dual Therapy Stent - Product Description
  • OrbusNeich - Ongoing Clinical Trials Overview
  • COMBO Dual Therapy Stent - Japan-USA Harmonized Assessment by Randomized, Multi-center Study of Orbusneich's Combo Stent (Japan-USA HARMONEE): Assessment of a Novel DES Platform for Percutaneous Coronary Revascularization in Patients with Ischemic Coronary Disease and NSTEMI Acute Coronary Syndrome
  • COMBO Dual Therapy Stent - Multicenter, Prospective, Clinical Outcomes After Deployment of the Abluminal Sirolimus Coated Bio-Engineered Stent (Combo Bio- Engineered Sirolimus Eluting Stent) Post Market Registry
  • COMBO Dual Therapy Stent - Multinational Abluminal Sirolimus Coated Bio-engineered Stent: The Mascot Post Marketing Registry
  • REVA Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Fantom Sirolimus-Eluting Bioresorbable Scaffold - Product Status
  • Fantom Sirolimus-Eluting Bioresorbable Scaffold - Product Description
  • ReZolve Sirolimus-Eluting Bioresorbable Coronary Scaffold - Product Status
  • ReZolve Sirolimus-Eluting Bioresorbable Coronary Scaffold - Product Description
  • ReZolve2 - Product Status
  • ReZolve2 - Product Description
  • Sino Medical-Device Technology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • BuMA Supreme DES - Product Status
  • BuMA Supreme DES - Product Description
  • Stentys, SA Pipeline Products & Ongoing Clinical Trials Overview
  • STENTYS Paclitaxel-Eluting Stent - Product Status
  • STENTYS Paclitaxel-Eluting Stent - Product Description
  • Svelte Medical Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Svelte Drug-Eluting Coronary Stent With IDS - Product Status
  • Svelte Drug-Eluting Coronary Stent With IDS - Product Description
  • Svelte Drug-Eluting Coronary Stent With Rapid-Exchange Delivery System - Product Status
  • Svelte Drug-Eluting Coronary Stent With Rapid-Exchange Delivery System - Product Description
  • Tepha, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • TephaFLEX Absorbable Stent - Product Status
  • TephaFLEX Absorbable Stent - Product Description
  • Terumo Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Bioresorbable Coronary Stent - Product Status
  • Bioresorbable Coronary Stent - Product Description
  • Ultimaster - Product Status
  • Ultimaster - Product Description
  • Ultimaster Line Extension - Product Status
  • Ultimaster Line Extension - Product Description
  • Terumo Corporation - Ongoing Clinical Trials Overview
  • Ultimaster - Prospective, Single Arm, Multi-centre, Observational Registry to Further Validate Safety and Efficacy of the Ultimaster Des System in Unselected Patients Representing Everyday Clinical Practice
  • Tryton Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Tryton Side Branch Short Stent - Product Status
  • Tryton Side Branch Short Stent - Product Description
  • Tryton Side Branch Stent System - Product Status
  • Tryton Side Branch Stent System - Product Description
  • University of Strathclyde Pipeline Products & Ongoing Clinical Trials Overview
  • CODE Drug-Eluting Stent - Product Status
  • CODE Drug-Eluting Stent - Product Description
  • Drug-Eluting Stent - Product Status
  • Drug-Eluting Stent - Product Description
  • VasoTech Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • PowerStent Absorb DES - Product Status
  • PowerStent Absorb DES - Product Description
  • PowerStent Coro DES - Product Status
  • PowerStent Coro DES - Product Description
  • Xenogenics Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Ideal BioStent - First Generation - Product Status
  • Ideal BioStent - First Generation - Product Description
  • Ideal BioStent - Second Generation - Product Status
  • Ideal BioStent - Second Generation - Product Description
  • Zorion Medical Pipeline Products & Ongoing Clinical Trials Overview
  • ZMED Absorbable Drug Eluting Stent - Product Status
  • ZMED Absorbable Drug Eluting Stent - Product Description
  • Glossary

List of Figures

  • Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
  • Drug Eluting Stents (DES) - Pipeline Products by Segment
  • Drug Eluting Stents (DES) - Pipeline Products by Territory
  • Drug Eluting Stents (DES) - Pipeline Products by Regulatory Path
  • Drug Eluting Stents (DES) - Pipeline Products by Estimated Approval Date
  • Drug Eluting Stents (DES) - Ongoing Clinical Trials
Back to Top